BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21538359)

  • 1. MDR1 (multidrug resistence 1) can regulate GCS (glucosylceramide synthase) in breast cancer cells.
    Zhang X; Wu X; Li J; Sun Y; Gao P; Zhang C; Zhang H; Zhou G
    J Surg Oncol; 2011 Oct; 104(5):466-71. PubMed ID: 21538359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
    Gouazé V; Liu YY; Prickett CS; Yu JY; Giuliano AE; Cabot MC
    Cancer Res; 2005 May; 65(9):3861-7. PubMed ID: 15867385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs.
    Sun Y; Zhang T; Gao P; Meng B; Gao Y; Wang X; Zhang J; Wang H; Wu X; Zheng W; Zhou G
    Breast Cancer Res Treat; 2010 Jun; 121(3):591-9. PubMed ID: 19693666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Construction of glucosylceramide synthase-specific siRNA expression vector and its efficiency in reversal of drug resistance in breast carcinoma cells].
    Sun YL; Zhou GY; Li KN; Li WT; Song XR; Gao P
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(8):518-21. PubMed ID: 15949329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-suppression of MDR1 (multidrug resistance 1) and GCS (glucosylceramide synthase) restores sensitivity to multidrug resistance breast cancer cells by RNA interference (RNAi).
    Zhang X; Li J; Qiu Z; Gao P; Wu X; Zhou G
    Cancer Biol Ther; 2009 Jun; 8(12):1117-21. PubMed ID: 19502811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells.
    Sun YL; Zhou GY; Li KN; Gao P; Zhang QH; Zhen JH; Bai YH; Zhang XF
    Neoplasma; 2006; 53(1):1-8. PubMed ID: 16416005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceramide glycosylation potentiates cellular multidrug resistance.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
    Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
    Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function.
    Chai L; McLaren RP; Byrne A; Chuang WL; Huang Y; Dufault MR; Pacheco J; Madhiwalla S; Zhang X; Zhang M; Teicher BA; Carter K; Cheng SH; Leonard JP; Xiang Y; Vasconcelles M; Goldberg MA; Copeland DP; Klinger KW; Lillie J; Madden SL; Jiang YA
    Int J Oncol; 2011 Mar; 38(3):701-11. PubMed ID: 21186402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells.
    Dönmez Y; Gündüz U
    Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of glucosylceramide synthase mRNA in vincristine-resistant KBV200 cell line in association with multidrug resistance].
    Yang Q; Zhang J; Wang SM; Zhang JR
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Jul; 24(7):779-81. PubMed ID: 15257901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of multidrug resistance, antisense RNA on the chemosensitivity of hepatocellular carcinoma cells.
    Li B; Ye T; Zhao L; Li DH; Gou XH; Zhao LY; Han L; Chen L; Yan LN; Gong JP
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):552-9. PubMed ID: 17085341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line.
    Lin X; Zhang X; Wang Q; Li J; Zhang P; Zhao M; Li X
    Neoplasma; 2012; 59(3):248-56. PubMed ID: 22329846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells.
    Xie P; Shen YF; Shi YP; Ge SM; Gu ZH; Wang J; Mu HJ; Zhang B; Qiao WZ; Xie KM
    Leuk Res; 2008 Mar; 32(3):475-80. PubMed ID: 17709137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin.
    Qi X; Chang Z; Song J; Gao G; Shen Z
    Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway.
    Turzanski J; Grundy M; Shang S; Russell N; Pallis M
    Exp Hematol; 2005 Jan; 33(1):62-72. PubMed ID: 15661399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
    Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.